Literature DB >> 15341932

Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine.

Oriol Pineda1, Jaume Farràs, Laura Maccari, Fabrizio Manetti, Maurizio Botta, Jaume Vilarrasa.   

Abstract

Microtubule-stabilising agents laulimalide and peloruside have been compared with tubulin-interacting drugs paclitaxel and colchicine by different computational approaches. Docking and QSAR-based programs point to a favourable interaction with the beta tubulin paclitaxel binding site, although an additional, preferred binding site has been found at the alpha subunit of tubulin. All together provides a plausible rationalisation of the singular binding features of these microtubule stabilisers and paves the way for future structural studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15341932     DOI: 10.1016/j.bmcl.2004.07.053

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  Cyclostreptin derivatives specifically target cellular tubulin and further map the paclitaxel site.

Authors:  Enrique Calvo; Isabel Barasoain; Ruth Matesanz; Benet Pera; Emilio Camafeita; Oriol Pineda; Ernest Hamel; Christopher D Vanderwal; José Manuel Andreu; Juan A López; José Fernando Díaz
Journal:  Biochemistry       Date:  2011-12-30       Impact factor: 3.162

2.  Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.

Authors:  Arun Kanakkanthara; Anja Wilmes; Aurora O'Brate; Daniel Escuin; Ariane Chan; Ada Gjyrezi; Janet Crawford; Pisana Rawson; Bronwyn Kivell; Peter T Northcote; Ernest Hamel; Paraskevi Giannakakou; John H Miller
Journal:  Mol Cancer Ther       Date:  2011-06-08       Impact factor: 6.261

3.  Theoretical and experimental study of polycyclic aromatic compounds as β-tubulin inhibitors.

Authors:  Fabian E Olazarán; Carlos A García-Pérez; Debasish Bandyopadhyay; Isaias Balderas-Rentería; Angel D Reyes-Figueroa; Lars Henschke; Gildardo Rivera
Journal:  J Mol Model       Date:  2017-02-18       Impact factor: 1.810

Review 4.  Peloruside, laulimalide, and noscapine interactions with beta-tubulin.

Authors:  Melissa M Gajewski; Laleh Alisaraie; Jack A Tuszynski
Journal:  Pharm Res       Date:  2012-06-26       Impact factor: 4.200

5.  Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.

Authors:  Adrian Begaye; Shana Trostel; Zhiming Zhao; Richard E Taylor; David C Schriemer; Dan L Sackett
Journal:  Cell Cycle       Date:  2011-10-01       Impact factor: 4.534

Review 6.  Epothilones: From discovery to clinical trials.

Authors:  Stefano Forli
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 7.  Strategies for the synthesis of the novel antitumor agent peloruside A.

Authors:  David R Williams; Partha P Nag; Nicolas Zorn
Journal:  Curr Opin Drug Discov Devel       Date:  2008-03

Review 8.  Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide.

Authors:  John H Miller; A Jonathan Singh; Peter T Northcote
Journal:  Mar Drugs       Date:  2010-03-31       Impact factor: 5.118

9.  Mutations in alpha-tubulin confer dinitroaniline resistance at a cost to microtubule function.

Authors:  Christopher Ma; Catherine Li; Lakshmi Ganesan; Jean Oak; Susan Tsai; David Sept; Naomi S Morrissette
Journal:  Mol Biol Cell       Date:  2007-09-19       Impact factor: 4.138

10.  A unique mode of microtubule stabilization induced by peloruside A.

Authors:  J Torin Huzil; John K Chik; Gordon W Slysz; Holly Freedman; Jack Tuszynski; Richard E Taylor; Dan L Sackett; David C Schriemer
Journal:  J Mol Biol       Date:  2008-03-19       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.